Published online before print April 5, 2004, doi: 10.1161/01.CIR.0000126284.40075.98
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:1704-1706.)
© 2004 American Heart Association, Inc.
Brief Rapid Communications |
Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival
A Prospective, Multicenter, Randomized Trial Comparing Infarct Artery Stenting Plus Abciximab With Stenting Alone
From the Division of Cardiology, Careggi Hospital, Florence, Italy (D.A., A.M., G.P., R.V., G.M., G.M.S.); Invasive Cardiology Department, Otamendi Hospital, Buenos Aires, Argentina (A.R.); and the Bernau Heart Center, Bernau, Germany (A.H.).
Correspondence to David Antoniucci, MD, Division of Cardiology, Careggi Hospital, Viale Morgagni, I-50134, Florence, Italy. E-mail carddept{at}tin.it
Received December 29, 2003; de novo received January 26, 2004; revision received February 24, 2004; accepted February 24, 2004.
Background— The impact on survival of routine use of abciximab as adjunctive treatment to routine infarct artery stenting for acute myocardial infarction is not defined. We sought to determine the effect of abciximab on 1-year survival and other major adverse cardiac events of patients with acute myocardial infarction undergoing routine infarct artery stenting.
Methods and Results— The Abciximab and Carbostent Evaluation (ACE) Trial is an unblinded, randomized, controlled trial that compared abciximab with placebo in patients undergoing routine infarct artery stent implantation for acute myocardial infarction. At 1 year, the survival rate was 95±2% in the abciximab group and 88±2% in the stent-alone group (P=0.017). The reinfarction rate was 1% in the abciximab group and 6.0% in the stent-alone group, whereas there were no differences between groups in target vessel revascularization rate (16.5% in the abciximab group, 17.5% in the stent-alone group).
Conclusions— Abciximab as adjunctive treatment to routine infarct artery stenting for acute myocardial infarction resulted in improved 1-year survival and lower reinfarction rates.
Key Words: myocardial infarction • stents • glycoproteins
This article has been cited by other articles:
 |
|
 |
|
  E. Di Lorenzo, G. De Luca, R. Sauro, A. Varricchio, M. Capasso, T. Lanzillo, F. Manganelli, C. Mariello, F. Siano, M. R. Pagliuca, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 515 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Brener The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect? J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1674 - 1676. [Full Text] [PDF]
|
|
|
|
|
|
G. Sardella, M. Mancone, C. Bucciarelli-Ducci, L. Agati, R. Scardala, I. Carbone, M. Francone, A. Di Roma, G. Benedetti, G. Conti, et al. Thrombus Aspiration During Primary Percutaneous Coronary Intervention Improves Myocardial Reperfusion and Reduces Infarct Size The EXPIRA (Thrombectomy With Export Catheter in Infarct-Related Artery During Primary Percutaneous Coronary Intervention) Prospective, Randomized Trial. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 309 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ortolani, A. Marzocchi, C. Marrozzini, T. Palmerini, F. Saia, N. Taglieri, F. Baldazzi, G. Dall'Ara, P. Nardini, S. Gianstefani, et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network Eur. Heart J., January 1, 2009; 30(1): 33 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Patel, H. Rana, and D. A. N. Mascarenhas Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 89 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al. Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial JAMA, April 16, 2008; 299(15): 1788 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Heer, U Zeymer, C Juenger, A K Gitt, H Wienbergen, R Zahn, M Gottwik, J Senges, and for the Acute Coronary Syndromes (ACOS) Registry I Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice Heart, October 1, 2006; 92(10): 1484 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The ADMIRAL Investigators Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study Eur. Heart J., December 1, 2005; 26(23): 2520 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Prasad and B J Gersh Management of microvascular dysfunction and reperfusion injury Heart, December 1, 2005; 91(12): 1530 - 1532. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dudek, W. Mielecki, A. Dziewierz, J. Legutko, and J. S. Dubiel The role of thrombectomy and embolic protection devices Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I15 - I20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Migliorini and D. Antoniucci Patient selection bias in primary percutaneous coronary intervention trials: a critical issue Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I21 - I26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Danzi, L. Mauri, and F. Sozzi Percutaneous coronary intervention and beyond for ST-elevation acute myocardial infarction Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K26 - K30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Valgimigli, G. Percoco, G. Cicchitelli, G. Campo, E. Gardini, L. Pellegrino, P. Malagutti, C. Giretti, and R. Ferrari New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K31 - K35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, R. Grimaldi, and M. Chiariello Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction QJM, September 1, 2005; 98(9): 633 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H R Andersen, C J Terkelsen, L Thuesen, L R Krusell, S D Kristensen, H E Botker, J F Lassen, and T T Nielsen Myocardial infarction centres: the way forward Heart, June 1, 2005; 91(suppl_3): iii12 - iii15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Valgimigli, G. Percoco, P. Malagutti, G. Campo, F. Ferrari, D. Barbieri, G. Cicchitelli, E. P. McFadden, F. Merlini, L. Ansani, et al. Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial JAMA, May 4, 2005; 293(17): 2109 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sciagra, G. Parodi, A. Pupi, A. Migliorini, R. Valenti, G. Moschi, G. M. Santoro, G. Memisha, and D. Antoniucci Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial J. Nucl. Med., May 1, 2005; 46(5): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Suryapranata, G De Luca, A W J van 't Hof, J P Ottervanger, J C A Hoorntje, J-H E Dambrink, A T M Gosselink, F Zijlstra, and M-J de Boer Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients Heart, May 1, 2005; 91(5): 641 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? Eur. Heart J., September 2, 2004; 25(18): 1562 - 1564. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., September 1, 2004; 9(5): e5 - e5. [Full Text] [PDF]
|
|
|
|
 |
|
 Abciximab Improves Survival After Primary PCI in High-Risk Patients Journal Watch Cardiology, June 25, 2004; 2004(625): 2 - 2. [Full Text]
|
|
|
|
 |
|
 R. SoRelle Cardiovascular News Circulation, April 13, 2004; 109(14): e9035 - e9035. [Full Text]
|
|